PITTSBURGH, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company dedicated to addressing serious diseases with significant unmet needs, ...
LP-310 shows significant improvements in pain and inflammation for oral lichen planus, with favorable safety results in Phase 2a trial. Lipella Pharmaceuticals has announced promising results from its ...
The "Clinical Snapshot" series provides a concise examination of a clinical presentation including history, treatment, patient education, and nursing measures. Using the format here, you are invited ...
A survey of US dermatologists revealed low screening rates for common comorbidities in patients with lichen planus (LP), with significant reliance on topical treatments. An anonymous survey with ...
Oral lichen planus (OLP) is a chronic, immune‐mediated mucosal disorder characterised by a range of clinical presentations, from asymptomatic reticular patterns to painful erosive lesions. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results